EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis

Benjamin Rix Brooks iD, Erik P Pioro iD, Takeshi Sakata, Fumihiro Takahashi iD, Melissa Hagan, Stephen Apple iD

Muscle & Nerve · 2023

DOI: 10.1002/mus.27946 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Muscle & Nerve, 2023. Verfasst von Benjamin Rix Brooks und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Planning LLC, Charlotte, North Carolina, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Intravenous (IV) edaravone is a US Food and Drug Administration–approved treatment for amyotrophic lateral sclerosis (ALS), shown in clinical trials to slow physical functional decline. In this study we compared the effect of IV edaravone (edaravone‐first group) versus placebo followed by IV edaravone (placebo‐first group) on survival and additional milestone events.

Methods

This work is a post hoc analysis of Study 19/MCI186‐19, which was a randomized, placebo‐controlled, phase 3 study investigating IV edaravone versus placebo. Study 19 and its 24‐week extension have been described previously (NCT01492686). Edaravone‐first versus placebo‐first group time to events for specific milestone(s) were analyzed post hoc. Time‐to‐event composite endpoints were time to death; time to death, tracheostomy, or permanent assisted ventilation (PAV); and time to death, tracheostomy, PAV, or hospitalization.

Results

The risk for death, tracheostomy, PAV, or hospitalization was 53% lower among patients in the edaravone‐first vs placebo‐first groups (hazard ratio = 0.47 [95% confidence interval 0.25 to 0.88], P = .02). The overall effect of IV edaravone on ALS progression could be seen in the significant separation of time‐to‐event curves for time to death, tracheostomy, PAV, or hospitalization. ALS survival composite endpoint analyses (ALS/SURV) suggested a treatment benefit (least‐squares mean difference) for the edaravone‐first versus the placebo‐first group at week 24 (0.15 ± 0.05 [95% confidence interval 0.06 to 0.25], P < .01) and week 48 (0.11 ± 0.05 [95% confidence interval 0.02 to 0.21], P = .02).

Discussion

These analyses illustrate the value of timely and continued IV edaravone treatment, as earlier initiation was associated with a lower risk of death, tracheostomy, PAV, or hospitalization in patients with ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisHumansEdaravoneTracheostomyProportional Hazards ModelsSurvival Analysis

Stichwörter der Autor:innen

amyotrophic lateral sclerosisintravenous edaravonemotor neuron diseasestudy 19survival

Substanzen

Edaravone

Autor:innen und Institutionen

  • Clinical Trials Planning LLC, Charlotte, North Carolina, USA.
  • Atrium Health Neuroscience Institute, Neuromuscular/ALS-MDA Care Center and ALSA Center of Excellence, Department of Neurology, Carolinas Medical Center, University of North Carolina School of Medicine-Charlotte Campus,…
  • Neuromuscular Division, Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.

ORCID-Profile: Benjamin Rix Brooks, Erik P Pioro, Fumihiro Takahashi, Stephen Apple

Zitieren

APA

Brooks, B. R., Pioro, E. P., Sakata, T., Takahashi, F., Hagan, M., & Apple, S. (2023). The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis. Muscle & Nerve. https://doi.org/10.1002/mus.27946

Vancouver

Brooks BR, Pioro EP, Sakata T, Takahashi F, Hagan M, Apple S. The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis. Muscle & Nerve. 2023. doi:10.1002/mus.27946

BibTeX
@article{Brooks2023,
  author = {Brooks, Benjamin Rix and Pioro, Erik P and Sakata, Takeshi and Takahashi, Fumihiro and Hagan, Melissa and Apple, Stephen},
  title = {The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis},
  journal = {Muscle & Nerve},
  year = {2023},
  doi = {10.1002/mus.27946}
}
Kostenlos starten →